TGTX | Ticker Profile - Titan Protect

TGTX

TG Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$40.16

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6.0B

Total market value of the company

Trailing P/E

13.71

Reasonably valued

Forward P/E

13.53

Based on estimated future earnings — lower means cheaper

Rev Growth

+69.6%

Year-over-year revenue change

Profit Margin

66.0%

How much profit the company keeps from each dollar of revenue

ROE

112.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$50.00

+25% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 7 analysts covering this stock

About TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

https://www.tgtherapeutics.com

Country: United States Employees: 399 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.065

Excellent risk-adjusted returns

Kelly Fraction

0.0896

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.296

Returns exceed worst-case losses — strong risk profile

Annual Return

54.4%

Historical annualised return based on price data

Max Drawdown

-42.0%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.68

Significantly more volatile than the market

52W High

$44.65

10% below the year high

52W Low

$25.28

59% above the year low

Avg Volume

2,063,701

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

26.5%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.86

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

129.23

Heavy leverage — higher financial risk if revenues decline

Current Ratio

5.81

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.85

Like current ratio but excludes inventory — stricter test

Gross Margin

83.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

17.0%

Profit from core operations before interest and tax

Free Cash Flow

$-30,164,876

Negative — the business is spending more than it generates

Revenue (TTM)

$700M

Total revenue over the last 12 months

Net Income

$462M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$70.00

Target Median

$50.00

Target Low

$17.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go